Close

The Medicare Interactive website just got an upgrade. Take a look today!

Medicare Watch

Medicare Watch articles are featured in Medicare Rights’ weekly newsletter, which helps readers stay updated on Medicare policy and advocacy developments and learn about changes in Medicare benefits and rules. Subscribe now by visiting www.medicarerights.org/newsletters.

New Report Details High Out-of-Pocket Costs for Some with Medicare

A new analysis from the Kaiser Family Foundation (KFF) underscores these challenges. According to the report, people with Original Medicare spent an average of $5,460 out of their own pockets for health care in 2016. Nearly half of this spending was for services outside of Medicare, such as LTSS (32%) and dental care (14%). The other half was largely devoted to meeting beneficiary cost-sharing obligations, including for provider-based care (22%) and prescription drugs (21%).

Read More »

Court Blocks Sweeping Rule that Would Negatively Impact Patient Access to Care

This week, a federal court blocked a Trump administration rule that would have allowed health plans and providers to refuse to provide certain types of care they disagreed with on moral or religious grounds. Set to take effect on November 22, the rule would have permitted individuals to deny care even in circumstances where performing the refused service was a significant portion of their jobs, and even where the refusal could prevent patients from receiving the service altogether.

Read More »

House Committees Advance Drug Pricing Legislation

In recent weeks, several committees within the U.S. House of Representatives—Energy & Commerce, Education & Labor, and Ways & Means—have been working to finalize the House’s drug pricing bill, HR 3. While the bill advanced by each committee differs slightly, the underlying goals are unchanged from the version initially introduced.

Read More »

Big Changes May Be in Store for Medicare Part D

Some changes are in store for Part D in 2020 and policymakers are contemplating even more. The Kaiser Family Foundation (KFF), a nonpartisan nonprofit focused on national health issues, recently outlined what the program will look like next year under current law, and under recent legislative and administrative proposals.

Read More »

U.S. House Moving Forward with Drug Pricing Bill

Lawmakers in the U.S. House of Representatives are continuing work on their drug pricing bill, H.R. 3, with hopes of holding a vote later this month.

Unveiled in September, H.R. 3 includes a number of provisions that would improve prescription drug access and affordability for people with Medicare. Among the bill’s critical reforms are those allowing Medicare to negotiate drug prices; the imposition of inflationary rebates on certain drugs in Parts B and D; and a restructuring of the Part D benefit that would cap out-of-pocket costs, reduce the federal government’s liability, and better align pricing incentives.

Read More »

Medicare Part B Premium Announced for 2020

Last week, the Centers for Medicare & Medicaid Services (CMS) announced
the Medicare Part B premium for 2020. Starting January 1, the standard Part B premium will increase from $135.50 to $144.60 per month.

New Report Details High Out-of-Pocket Costs for Some with Medicare

A new analysis from the Kaiser Family Foundation (KFF) underscores these challenges. According to the report, people with Original Medicare spent an average of $5,460 out of their own pockets for health care in 2016. Nearly half of this spending was for services outside of Medicare, such as LTSS (32%) and dental care (14%). The other half was largely devoted to meeting beneficiary cost-sharing obligations, including for provider-based care (22%) and prescription drugs (21%).

Court Blocks Sweeping Rule that Would Negatively Impact Patient Access to Care

This week, a federal court blocked a Trump administration rule that would have allowed health plans and providers to refuse to provide certain types of care they disagreed with on moral or religious grounds. Set to take effect on November 22, the rule would have permitted individuals to deny care even in circumstances where performing the refused service was a significant portion of their jobs, and even where the refusal could prevent patients from receiving the service altogether.

House Committees Advance Drug Pricing Legislation

In recent weeks, several committees within the U.S. House of Representatives—Energy & Commerce, Education & Labor, and Ways & Means—have been working to finalize the House’s drug pricing bill, HR 3. While the bill advanced by each committee differs slightly, the underlying goals are unchanged from the version initially introduced.

Big Changes May Be in Store for Medicare Part D

Some changes are in store for Part D in 2020 and policymakers are contemplating even more. The Kaiser Family Foundation (KFF), a nonpartisan nonprofit focused on national health issues, recently outlined what the program will look like next year under current law, and under recent legislative and administrative proposals.

U.S. House Moving Forward with Drug Pricing Bill

Lawmakers in the U.S. House of Representatives are continuing work on their drug pricing bill, H.R. 3, with hopes of holding a vote later this month.

Unveiled in September, H.R. 3 includes a number of provisions that would improve prescription drug access and affordability for people with Medicare. Among the bill’s critical reforms are those allowing Medicare to negotiate drug prices; the imposition of inflationary rebates on certain drugs in Parts B and D; and a restructuring of the Part D benefit that would cap out-of-pocket costs, reduce the federal government’s liability, and better align pricing incentives.